Ushering in a New Era of Sustainable Weight Loss with Incretin-Based Therapies

Ushering in a New Era of Sustainable Weight Loss with Incretin-Based Therapies (March 2021)

Saturday, March 20, 2021
Webinar -- 5:30 PM ET
https://www.clinicaloptions.com/ObesityENDO2021Join1

Agenda

5:30 PM Welcome and Program Overview

5:35 PM Metabolic Adaptation to Weight Loss in Patients with Obesity

5:55 PM Actions of Incretin-Based Therapies on Weight Loss and the Value of Sustained Weight Loss in Patients with Obesity and Related Comorbidities

6:25 PM Current and Emerging Incretin-Based Drug Therapy for Long-term Weight Management

6:45 PM Question and Answer Session

7:00 PM Adjournment

*Attendees must be registered for ENDO 2021 to participate.

https://www.endocrine.org/meetings-and-events/endo2021/endo-2021-registration

Faculty

Program Director
Kristina Utzschneider, MD

Assistant Professor, Medicine
Division of Metabolism, Endocrinology and Nutrition
University of Washington
Director, VA Diabetes Care Program
VA Puget Sound Health Care System
Seattle, Washington

Faculty
Randy Seeley, PhD

Professor of Surgery
University of Michigan Department of Surgery
Director, Michigan Nutrition Obesity Research Center
Ann Arbor, MI

Faculty
Jenny Tong, MD, MPH

Associate Professor
Endocrine Section Head
VA Puget Sound Health System
Division of Metabolism, Endocrinology, and Nutrition
University of Washington
Seattle, WA

SPC Liaison
Amy E. Rothberg, MD, PhD

Associate Professor, Internal Medicine and Nutritional Science
University of Michigan
Ann Arbor, Michigan

Goal Statement
The goals of this program are to improve clinician understanding of:

  • The metabolic adaptation in obesity
  • The value of sustained weight loss and related complications
  • The latest evidence for incretin-based therapies for long-term weight management

Target Audience
The live, virtual symposium is designed to meet the educational needs of endocrinologists (physicians and fellows), internists, primary care physicians, endocrine nurses, pharmacists, and other advanced practice professionals who will attend ENDO 2021 and care for individuals with obesity. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Examine the metabolic adaptations that contribute to weight loss challenges in patients with obesity
  • Describe the physiologic and metabolic effects of incretin-based therapies that lead to weight loss in patients with obesity and the benefits of sustained weight loss on obesity-related comorbidities
  • Summarize the long-term efficacy and safety data of current and emerging incretin-based therapies for the treatment of patients with obesity

Accreditation

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.

The Endocrine Society designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification (MOC):
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by The Endocrine Society and Clinical Care Options, LLC (CCO). Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-9999-21-018-L01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.